Global Spinal Cord Stimulation Market Grows Steadily at a CAGR of 7.88%

Introduction

Spinal Cord Stimulation (SCS) is a therapeutic approach used to alleviate chronic pain, particularly in the back, legs, or arms. The procedure involves placing a small device near the spinal cord, which delivers gentle electrical pulses. These pulses disrupt the transmission of pain signals to the brain, helping to reduce the perception of pain. SCS is generally considered for individuals who have not experienced sufficient relief from medications or surgical interventions. This treatment is both adjustable and reversible, offering a significant improvement in quality of life for those suffering from ongoing or nerve-related pain.

Market Dynamics

Rising prevalence of chronic pain disorders drives the global market

The increasing incidence of chronic pain conditions is a key factor driving the growth of the spinal cord stimulation market, as more patients turn to long-term solutions when traditional treatments prove ineffective. Conditions such as failed back surgery syndrome (FBSS) and complex regional pain syndrome (CRPS) are now commonly treated with spinal cord stimulation, owing to its proven ability to alleviate pain and enhance mobility.

• Research published by the National Center for Biotechnology Information (NCBI) indicates that FBSS affects around 20–40% of individuals following spinal surgery, often resulting in ongoing and severe pain. Meanwhile, CRPS impacts an estimated 200,000 people each year in the United States.

With the prevalence of these disorders on the rise, the demand for advanced neuromodulation techniques like spinal cord stimulators is anticipated to increase consistently in the coming years.

Development of non-invasive or minimally invasive stimulation systems creates tremendous opportunities

A key growth opportunity in the global spinal cord stimulation market is the development of non-invasive or minimally invasive stimulation systems, which aim to reduce surgical risks and improve treatment accessibility. These cutting-edge technologies are especially beneficial for patients who are not eligible for traditional implantable devices.

• For example, in December 2024, ONWARD Medical secured FDA de novo clearance for its ARC-EX system—the first non-invasive spinal cord stimulation device approved to improve hand function and sensation in individuals with chronic spinal cord injuries. The system delivers electrical stimulation through electrodes placed externally on the back of the neck, eliminating the need for surgical procedures.

These advancements reflect a broader industry trend toward safer, more user-friendly neuromodulation solutions that enhance patient outcomes while helping to lower overall healthcare costs.

Regional Analysis

North America holds a leading position in the global spinal cord stimulation market, supported by its well-established healthcare infrastructure, favorable insurance coverage, and widespread awareness of neuromodulation treatments. The United States, in particular, experiences high adoption rates due to the increasing incidence of chronic pain conditions like failed back surgery syndrome and diabetic neuropathy. As reported by the CDC, around 20% of U.S. adults are affected by chronic pain, which drives the demand for spinal cord stimulators.

Moreover, major industry players such as Boston Scientific and Medtronic, both based in the region, continue to introduce advanced technologies, including Medtronic’s Intellis™ platform. The availability of skilled neurosurgeons and dedicated pain management centers ensures greater patient access to these cutting-edge therapies, further strengthening North America's dominance in the market.

Key Highlights

• The global spinal cord stimulation market size was valued at USD 3.14 billion in 2024 and is estimated to grow from USD 3.38 billion in 2025 to reach USD 6.21 billion by 2033, growing at a CAGR of 7.88% during the forecast period (2025–2033).
• By product type, the global spinal cord stimulation market is segmented intorechargeable spinal cord stimulators and non-rechargeable spinal cord stimulators.
• By application, the market is divided into failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), degenerative disk disease, ischemic limb pain, and others.
• By end-user, the market is divided into hospitals, ambulatory surgical centers, specialty clinics, and others.
• North America is the highest shareholder in the global market.

Competitive Players

1. Medtronic plc
2. Boston Scientific Corporation
3. Abbott Laboratories
4. Nevro Corp.
5. Saluda Medical Pty Ltd
6. Nuvectra Corporation (assets acquired by NeuroNexus)
7. Stimwave Technologies Inc.
8. MicroTransponder Inc.
9. Synapse Biomedical Inc.
10. Biotronik SE & Co. KG

Recent Developments

• In January 2025, Saluda Medical, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its innovative biomarker-driven, automated patient programming platform designed for spinal cord stimulation (SCS). This development marks a major step forward in SCS therapy. The new platform, known as EVA™, is fully compatible with all Evoke® System implants currently in use across the U.S.

Segmentation

1. By Product Type
   1. Rechargeable Spinal Cord Stimulators
   2. Non-Rechargeable Spinal Cord Stimulators
2. By Application
   1. Failed Back Surgery Syndrome (FBSS)
   2. Complex Regional Pain Syndrome (CRPS)
   3. Degenerative Disk Disease
   4. Ischemic Limb Pain
   5. Others
3. By End-User
   1. Hospitals
   2. Ambulatory Surgical Centers
   3. Specialty Clinics
   4. Others